Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nature Medicine

• Publication date

  2003-11-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nm955PMID 14595408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption.

  2002cited by this paper
• Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis.

  2002cited by this paper
• New regulatory co-receptors: inducible co-stimulator and PD-1.

  2002cited by this paper
• Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys.

  2002cited by this paper
• The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.

  2001cited by this paper
• Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin Substitution

  2001cited by this paper
• Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.

  2001cited by this paper
• ESDN, a Novel Neuropilin-like Membrane Protein Cloned from Vascular Cells with the Longest Secretory Signal Sequence among Eukaryotes, Is Up-regulated after Vascular Injury*

  2001cited by this paper
• beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes.

  2001cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Transgenic mouse model of stunned myocardium.

  2000cited by this paper
• Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin

  2000cited by this paper
• Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator.

  1999cited by this paper
• Troponin I, stunning, hypertrophy, and failure of the heart.

  1999cited by this paper
• The role of cytoskeletal proteins in cardiomyopathies.

  1998cited by this paper
• Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12

  1998cited by this paper
• A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

  1998cited by this paper
• Slow inactivation of cardiac L-type Ca2+ channel induced by cold acclimation of guinea pig.

  1998cited by this paper
• Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments.

  1998cited by this paper
• Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy

  1997cited by this paper
• Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research.

  1997cited by this paper
• Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis.

  1997cited by this paper
• Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits.

  1997cited by this paper
• Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

  1996cited by this paper
• Myocardial markers of injury. Evolution and insights.

  1996cited by this paper
• Localization of Rabphilin-3A on the synaptic vesicle.

  1994cited by this paper
• Concepts of autoimmunity applied to idiopathic dilated cardiomyopathy.

  1993cited by this paper
• Cardiac myosin-induced myocarditis. Heart autoantibodies are not involved in the induction of the disease.

  1990cited by this paper
• Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy.

  1990cited by this paper
• Antibody-mediated enhancement of calcium permeability in cardiac myocytes

  1988cited by this paper
• Heart-specific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens.

  1987cited by this paper
• Cardiac myosin induces myocarditis in genetically predisposed mice.

  1987cited by this paper
• The ADP/ATP Carrier as a MitochondriaL Auto‐antigen—Facts and Perspectives

  1986cited by this paper
• Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy.

  1983cited by this paper
• Calcium tolerant ventricular myocytes prepared by preincubation in a “KB medium”

  1982cited by this paper
• An Experimental Model for Congestive Heart Failure After Encephalomyocarditis Virus Myocarditis in Mice

  1982cited by this paper
• Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

  1981cited by this paper
• Electrical properties of individual cells isolated from adult rat ventricular myocardium.

  1980cited by this paper

• Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets.

  2026cites this paper
• Caught in the crossfire: cardiac complications of cancer therapy

  2026cites this paper
• Pathological mechanisms and treatment strategies for immune checkpoint inhibitor-associated myocarditis: insights from single-cell sequencing.

  2026cites this paper
• Nicotinamide prevents anti-PD1 immune checkpoint inhibitor-associated early stages of cardiotoxicity.

  2026cites this paper
• Identification of features and differences in PD-1 inhibitor-associated myocarditis and acute myocardial infarction using proteomic analysis: A clinical and preclinical study.

  2025cites this paper
• Potencial Terapêutico da Vortioxetina: Respostas Cardíacas ao Estresse Crônico Moderado Imprevisível em um Modelo de Rato

  2025cites this paper
• Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management

  2025cites this paper
• IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity

  2025cites this paper
• Cardiovascular Risk Profile of Nivolumab Anti-cancer Therapy

  2025cites this paper
• Associations Between Pre‐Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Cardiac Troponin I Antibodies Induce Cardiomyocyte Damage and Alter Cell Morphology

  2025influential citation
• The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

  2025cites this paper
• Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against αPD1-induced cardiotoxicity in mice

  2025cites this paper
• Probing the association between PD-1/PD-L1 expression and atrial fibrillation in peripheral blood of Han and Kazakh populations in Xinjiang region

  2025cites this paper
• Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis

  2025cites this paper
• Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis

  2025influential citation
• SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk

  2025cites this paper
• Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events.

  2025cites this paper
• Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis

  2025cites this paper
• Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells

  2025cites this paper
• A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers

  2025cites this paper
• Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy.

  2025cites this paper
• Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody–drug conjugates: Case reports and management strategies

  2025cites this paper
• Longitudinal Evaluation of Immune Checkpoint Inhibitor‐Induced Fatigue Syndrome by Rest, Stress, and Speckle‐Tracking Strain Echocardiography

  2025cites this paper
• Cardiovascular adverse effects of immunotherapy in cancer: insights and implications

  2025cites this paper
• Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy.

  2025cites this paper
• Vortioxetine’s Therapeutic Potential: Cardiac Responses to Chronic Unpredictable Mild Stress in a Rat Model

  2025cites this paper
• Cancer-Related Immune Therapies

  2025cites this paper
• Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: update on recent developments.

  2025cites this paper
• The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure

  2025cites this paper
• Troponin i-induced cardiac inflammation and dysfunction in mice: a comparative study with the AT-3 tumor-bearing model

  2025cites this paper
• Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics.

  2025cites this paper
• Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart

  2024cites this paper
• Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements

  2024cites this paper
• Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

  2024cites this paper
• Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer

  2024cites this paper
• Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

  2024cites this paper
• Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)

  2024cites this paper
• Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System

  2024cites this paper
• An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury

  2024cites this paper
• Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction

  2024cites this paper
• Changes in tumor and cardiac metabolism upon immune checkpoint

  2024cites this paper
• Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

  2024cites this paper
• Pathophysiological mechanisms underlying increased circulating cardiac troponin in noncardiac surgery: a narrative review.

  2024cites this paper
• Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti-PD-1 Immune Checkpoint Inhibitor Cancer Therapy.

  2024cites this paper
• Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy

  2024cites this paper
• Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.

  2024cites this paper
• Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4+Foxp3+ Regulatory T Cell Immunosuppression

  2024cites this paper
• Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure

  2024cites this paper
• Immune checkpoint inhibitor-associated cardiovascular toxicities: A review

  2024cites this paper
• Factors associated with immune‑related severe adverse events (Review)

  2024cites this paper
• Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care

  2024cites this paper
• The PD-1–PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration

  2024cites this paper
• Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies

  2024cites this paper
• Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.

  2024cites this paper
• Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination

  2024cites this paper
• Cardiovascular toxicity with CTLA‐4 inhibitors in cancer patients: A meta‐analysis

  2024cites this paper
• Insight of immune checkpoint inhibitor related myocarditis.

  2024cites this paper
• Increase of Cardiac Autoantibodies Against Beta-2-adrenergic Receptor During Acute Cellular Heart Transplant Rejection

  2024cites this paper
• Autoimmune Myocarditis, Old Dogs and New Tricks

  2024cites this paper
• The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients

  2024cites this paper
• Functions and Clinical Significance of Myocardial Cell-Derived Immunoglobulins.

  2024cites this paper
• Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review

  2024cites this paper
• Multicentre, randomized, double‐blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO‐DCM): Rationale and design

  2024cites this paper
• Flotillin-2 dampens T cell antigen sensitivity and functionality

  2024cites this paper
• Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation

  2024cites this paper
• Genetic factors in the pathogenesis of cardio-oncology

  2024cites this paper
• Mechanisms of myocardial toxicity of antitumor drugs and potential therapeutic strategies: A review of the literature.

  2024cites this paper
• An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury

  2024cites this paper
• PD-L1 and PD-1 in Immune Regulation and Their Implications in Blood Cancers

  2024cites this paper
• Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review

  2024cites this paper
• Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models

  2023cites this paper
• Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review

  2023cites this paper
• Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis

  2023cites this paper
• Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.

  2023cites this paper
• Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications

  2023cites this paper
• Cardiac Troponin, Cognitive Function, and Dementia: A Systematic Review

  2023cites this paper
• Generation and Immuno-inflammatory Checkpoints in Oral Cavity Cancers

  2023cites this paper
• Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

  2023cites this paper
• Advances in immune checkpoint inhibitors induced-cardiotoxicity

  2023cites this paper
• A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors

  2023cites this paper
• Severe acute myositis and myocarditis upon initiation of six-weekly Pembrolizumab post-COVID-19 mRNA vaccination

  2023influential citation
• Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor‐associated lethal myocarditis in mice

  2023cites this paper
• Research Progress on Cardiotoxicity Associated with Immune Checkpoint Inhibitors

  2023cites this paper
• The knowns and unknowns of cardiac autoimmunity in viral myocarditis

  2023cites this paper
• Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

  2023cites this paper
• Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.

  2023cites this paper
• Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors

  2023cites this paper
• Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

  2023cites this paper
• The Balance of CD8-Positive T Cells and PD-L1 Expression in the Myocardium Predicts Prognosis in Lymphocytic Fulminant Myocarditis

  2023cites this paper
• The role of IL-6, IL-10, TNF-α and PD-1 expression on CD4 T cells in atrial fibrillation

  2023cites this paper
• The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

  2023cites this paper
• Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

  2023cites this paper
• Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease

  2023cites this paper
• Cardiac Autoantibodies Against Cardiac Troponin I in Post-Myocardial Infarction Heart Failure: Evaluation in a Novel Murine Model and Applications in Therapeutics

  2023cites this paper
• Association between immune checkpoint inhibitor‐induced myocarditis and concomitant use of thiazide diuretics

  2023cites this paper
• Myocarditis and autoimmunity

  2023cites this paper
• Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

  2023cites this paper
• Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

  2023cites this paper
• Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

  2023cites this paper